Ticker

Cerus (NASDAQ: CERS - Get Free Report) and Akanda (NASDAQ: AKAN - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends. Profitability This table compares Cerus and Akanda's net margins,

Toronto, Ontario--(Newsfile Corp. - April 9, 2026) - Akanda Corp. (NASDAQ: AKAN) (the "Company" or "Akanda"), today announced that it expects to implement a 1-for-4.5 reverse stock split of the Company's common shares effective April 13, 2026. The reverse stock split was previously approved by the Company's shareholders on November 28, 2025 and Board of Directors on March 23, 2026 and will begin trading on an…

Toronto, Ontario--(Newsfile Corp. - April 7, 2026) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company") today announced that on March 31, 2026, it convened and subsequently adjourned its Special Meeting of Shareholders (the "Meeting") without transacting any business due to the absence of a quorum. The Meeting has been adjourned and will be reconvened in person in Toronto, Ontario on Monday, April 27, 2026 at…

Akanda (NASDAQ: AKAN - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership. Risk and Volatility Akanda has a beta of

Akanda Corp. (NASDAQ: AKAN - Get Free Report) saw a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling 16,554 shares, a decline of 34.3% from the February 26th total of 25,178 shares. Based on an average trading volume of 73,209 shares, the days-to-cover ratio is